This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/wales/mid/7656676.stm
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
Version 0 | Version 1 |
---|---|
Protein key in new uni TB vaccine | Protein key in new uni TB vaccine |
(about 8 hours later) | |
Ground-breaking research by scientists in Wales and Russia is being used to develop a new vaccine for tuberculosis. | Ground-breaking research by scientists in Wales and Russia is being used to develop a new vaccine for tuberculosis. |
Aberystwyth University and the Russian Academy of Sciences have been working in partnership for a decade. | Aberystwyth University and the Russian Academy of Sciences have been working in partnership for a decade. |
Scientists discovered a new protein in humans in the late 1990s, which is now being developed to control bacteria which cause tuberculosis (TB). | Scientists discovered a new protein in humans in the late 1990s, which is now being developed to control bacteria which cause tuberculosis (TB). |
Clinical trials are to begin in 2009 but a charity says it could be 10 years before it is available for general use. | Clinical trials are to begin in 2009 but a charity says it could be 10 years before it is available for general use. |
TB kills 1.7m people each year, and there are concerns that the bacteria which causes it are becoming resistant to current drugs. | TB kills 1.7m people each year, and there are concerns that the bacteria which causes it are becoming resistant to current drugs. |
The only existing TB vaccine, Bacille Calmette-Guérin (BCG), which was created in 1921, is only partially effective. Our discovery... might help prevent the establishment of persistent infections in the first place Professor Mike Young | |
It is hoped the new vaccine will have more success treating sufferers, particularly in the developing world. | It is hoped the new vaccine will have more success treating sufferers, particularly in the developing world. |
It could work in three ways. | It could work in three ways. |
Firstly, by activating the dormant TB allowing it to be treated with drugs. Secondly, by ensuring the bacteria stays dormant and finally by working as a traditional vaccine preventing the bacteria from establishing. | Firstly, by activating the dormant TB allowing it to be treated with drugs. Secondly, by ensuring the bacteria stays dormant and finally by working as a traditional vaccine preventing the bacteria from establishing. |
Professor Mike Young, of Aberystwyth's Institute of Biological, Environmental and Rural Studies, helped lead the research team in mid Wales. | Professor Mike Young, of Aberystwyth's Institute of Biological, Environmental and Rural Studies, helped lead the research team in mid Wales. |
He said: "Current TB treatments can go on for over six months and can still leave bacteria in the body that can cause the disease when they resume active growth and multiplication. | He said: "Current TB treatments can go on for over six months and can still leave bacteria in the body that can cause the disease when they resume active growth and multiplication. |
"Our discovery, which is now being developed into a vaccine, might help prevent the establishment of persistent infections in the first place or, alternatively, it might prevent persisting organisms in individuals with latent TB from reawakening at all. | "Our discovery, which is now being developed into a vaccine, might help prevent the establishment of persistent infections in the first place or, alternatively, it might prevent persisting organisms in individuals with latent TB from reawakening at all. |
"TB kills around 1.7m people around the world every year. I hope that our research will now be rapidly translated into a vaccine that can help as many of these people as possible." | "TB kills around 1.7m people around the world every year. I hope that our research will now be rapidly translated into a vaccine that can help as many of these people as possible." |
'Positive sign' | 'Positive sign' |
Work started on the vaccine in the late 1990s, when researchers discovered a new family of proteins able to "resuscitate bacteria" found harmlessly in and around the human body. | Work started on the vaccine in the late 1990s, when researchers discovered a new family of proteins able to "resuscitate bacteria" found harmlessly in and around the human body. |
When "awoken from dormancy" researchers found the TB bacteria were much more susceptible to attack from antibiotics. | When "awoken from dormancy" researchers found the TB bacteria were much more susceptible to attack from antibiotics. |
The Aeras Global TB Vaccine Foundation, which was founded to develop new, cost-effective TB vaccines for use in the developing world, has licensed the discovery of the protein. | The Aeras Global TB Vaccine Foundation, which was founded to develop new, cost-effective TB vaccines for use in the developing world, has licensed the discovery of the protein. |
The charity TB Alert said this was a "positive sign" but the organisation's chair Paul Sommerfeld warned that a vaccine was still a long way off. | The charity TB Alert said this was a "positive sign" but the organisation's chair Paul Sommerfeld warned that a vaccine was still a long way off. |
"We're very happy that new work is being carried out, but there is a long period of testing, involving some three phases, and we're not expecting a new vaccine for about 10 years," he said. | "We're very happy that new work is being carried out, but there is a long period of testing, involving some three phases, and we're not expecting a new vaccine for about 10 years," he said. |
Previous version
1
Next version